Nickerson H J, Nesbit M E, Grosfeld J L, Baehner R L, Sather H, Hammond D
Med Pediatr Oncol. 1985;13(5):261-8. doi: 10.1002/mpo.2950130504.
Clinical staging and factors related to survival were evaluated in 44 stage IV-S and 44 stage IV patients with neuroblastoma, ages 0 to 12 months, seen at Children's Cancer Study Group (CCSG) institutions from 1972 to 1979. In 73 patients with complete surgical staging, the life-table projected survival at 3 years was 91% for stage IV-S and 44% for stage IV. The only deaths in stage IV-S disease occurred in three patients less than 2 months old at diagnosis. In stage IV-S, 3 to 12 months old at diagnosis, the disease-free survival was 97%. Chemotherapy or radiation therapy did not appear to improve the survival rate in stage IV-S. These studies further document a significant clinical and biologic difference between patients with stage IV and stage IV-S neuroblastoma and suggest that they require different therapeutic management.
对1972年至1979年期间在儿童癌症研究组（CCSG）机构就诊的44例IV - S期和44例IV期神经母细胞瘤患儿（年龄0至12个月）的临床分期及生存相关因素进行了评估。在73例接受完整手术分期的患者中，生命表预测的3年生存率IV - S期为91%，IV期为44%。IV - S期仅有的死亡发生在3例诊断时年龄小于2个月的患者中。在IV - S期，诊断时年龄为3至12个月的患者，无病生存率为97%。化疗或放疗似乎并未提高IV - S期的生存率。这些研究进一步证明了IV期和IV - S期神经母细胞瘤患者之间存在显著的临床和生物学差异，并表明它们需要不同的治疗管理。
